About Laminar Pharma
Laminar Pharma is a company based in Palma (Spain) founded in 2006. Laminar Pharma has raised $14.71 million across 5 funding rounds from investors including European Union, Fundación Alba Pérez and Dentol Capital. Laminar Pharma offers products and services including LAM561, LAM226, and LAM204. Laminar Pharma operates in a competitive market with competitors including Jazz Pharmaceuticals, Merck, Roivant Sciences, Gilead and Lilly, among others.
- Headquarter Palma, Spain
-
Sectors
Healthcare
-
Email
Locked
-
Phone
Locked
-
Website
Locked
-
Social
Locked
- Legal Name Laminar Pharmaceuticals S.A.
-
Annual Revenue
Not available
-
Net Profit
Not available
-
EBITDA
Not available
-
Total Equity Funding
$14.71 M (USD)
in 5 rounds
-
Latest Funding Round
$6.27 M (USD), Series A
Jul 19, 2024
-
Investors
European Union
& 3 more
-
Employee Count
Not available
Unlock complete access to The Company Check
Get unrestricted viewing across everything we track — from companies and brands to investors, funding rounds, acquisitions, financials, and more.
- Unlimited viewing on all profiles Companies, investors, financials, funding, acquisitions & directors
- Full access to every database India & global coverage, advanced filters and rich profile details
- Always-on access from your team account Single premium plan for everything you see on the portal
Products & Services of Laminar Pharma
Laminar Pharma offers a comprehensive portfolio of products and services, including LAM561, LAM226, and LAM204.
Drug for glioblastoma treatment in clinical trials
Molecule targeting specific diseases like cancers
Innovative compound for unmet medical needs
People of Laminar Pharma
Unlock access to complete
Funding Insights of Laminar Pharma
Laminar Pharma has successfully raised a total of $14.71M across 5 strategic funding rounds. The most recent funding activity was a Series A round of $6.27 million completed in July 2024. This substantial capital infusion reflects strong investor confidence in the company's business model, growth potential, and market opportunities. The funding enables strategic expansion, product development, market penetration, and operational scaling to drive long-term value creation and competitive advantage.
Investors in Laminar Pharma
Laminar Pharma has secured backing from 4 investors, including institutional and venture fund investors. Prominent investors backing the company include European Union, Fundación Alba Pérez and Dentol Capital.
| Investor | Description | Founded Year | Domain | Location |
|---|---|---|---|---|
|
-
|
Locked | Locked | Locked | |
|
Funds are raised by Fundación Alba Pérez for childhood cancer research.
|
Locked | Locked | Locked | |
|
-
|
Locked | Locked | Locked |
Investor details for Laminar Pharma
Investor domains, locations, round participation, and complete history require an active premium plan.
- Investor domains
- Investor locations
- Funding rounds
- Participation history
Verified entity values are shown only after access is granted.
Investments & Acquisitions by Laminar Pharma
Investment portfolio details for Laminar Pharma
Portfolio company identities, transaction dates, round details, and investment values require an active premium plan.
- Portfolio identities
- Transaction dates
- Round details
- Investment values
Verified entity values are shown only after access is granted.
Financial Statements - Laminar Pharma
Detailed financials for Laminar Pharma
Historical revenue, profit, statement rows, ratios, and trend charts require an active premium plan.
- Historical revenue
- Profit trends
- Statement rows
- Financial ratios
Verified entity values are shown only after access is granted.
Laminar Pharma Comparisons
Peer comparison for Laminar Pharma
Named peer metrics, headcount, funding, location, and side-by-side benchmarks require an active premium plan.
- Named peers
- Headcount comparison
- Funding comparison
- Operating benchmarks
Verified entity values are shown only after access is granted.
Competitors of Laminar Pharma
Laminar Pharma operates in a dynamic and competitive business environment, facing competition from various established players and emerging companies in the market. The competitive landscape includes prominent companies such as Jazz Pharmaceuticals, Merck, Roivant Sciences, Gilead and Lilly, among others.
| Company Name | Domain | Founded year | HQ Location | Description |
|---|---|---|---|---|
| Locked | Locked | Locked |
Novel biopharmaceutical medicines are developed for unmet medical needs.
|
|
| Locked | Locked | Locked |
Pharmaceutical products are manufactured and marketed worldwide.
|
|
| Locked | Locked | Locked |
Therapeutics for neurology, oncology, rare, and endocrinology diseases are developed.
|
|
| Locked | Locked | Locked |
Developer of medicines to treat HIV/AIDS, liver diseases, cancer & others
|
|
| Locked | Locked | Locked |
Traditional pharmaceutical medicines are developed for multiple health fields.
|
|
| Locked | Locked | Locked |
Novel dermatologic therapies are developed for skin conditions.
|
Detailed competitors of Laminar Pharma
Competitor domains, locations, full profiles, and operating metrics require an active premium plan.
- Domains and locations
- Full company profiles
- Operating metrics
- Competitive positioning
Verified entity values are shown only after access is granted.
Latest news on Laminar Pharma
Complete news archive for Laminar Pharma
Full article history, source details, and older brand coverage require an active premium plan.
- Full article archive
- Source and publication date
- Older coverage
- Brand-specific news history
Verified entity values are shown only after access is granted.
Frequently Asked Questions about Laminar Pharma
Laminar Pharma was founded in 2006 and raised its 1st funding round 11 years after it was founded.
Laminar Pharma is headquartered in Palma, Spain. It is registered at Palma, Balearic Islands, Spain.
Laminar Pharma is a funded company, having raised a total of $14.71M across 5 funding rounds to date.
Developer of melipathy based drugs. The company provides various products such as LAM561 anticancer drug acting through cell membrane modification, LAM226 Omega-3 lipid derivative which specifically targets neuronal membranes for Alzheimers, LAM204 polyunsaturated fatty acid to replace steroid anti-inflammatory treatments and LAM30171 fatty acid derivative as a potential treatment for cancer and metabolic disorders.
Laminar Pharma's top competitors include Merck, Roivant Sciences and Jazz Pharmaceuticals.
Laminar Pharma offers LAM561, LAM226, and LAM204.
Laminar Pharma has 4 investors. Key investors include European Union, Fundación Alba Pérez, Dentol Capital, and Matutes family.